Niox Group Stock

Niox Group Net Margin

The Net Profit Margin of Niox Group (NIOX.L) as of Aug 22, 2026 is 8.85 %. In the previous year, Net Profit Margin was 29.08 % — a change of -69.56% (lower).

Net Margin

8.85 %

YoY

-69.56%

Last updated:

Net Profit Margin of Niox Group is 2026 8.85 % . Net Profit Margin of Niox Group was 2025 29.08 % . It decreases by -69.56% lower compared to the previous year.

Niox Group's net margin stands at 8.9%, up from -140.2% several years earlier.

The Niox Group Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2017
-214.04 GBP
Jan 1, 2018
-242.44 GBP
Jan 1, 2019
-139.60 GBP
Jan 1, 2020
-140.17 GBP
Jan 1, 2021
12.90 GBP
Jan 1, 2022
51.44 GBP
Jan 1, 2023
29.08 GBP
Jan 1, 2024
8.85 GBP
The Niox Group Net Margin history
YEARNet MarginYoY
8.85 %-69.56%
29.08 %-43.47%
51.44 %+298.64%
12.90 %-109.21%
-140.17 %+0.41%
-139.60 %-42.42%
-242.44 %+13.27%
-214.04 %-63.99%
-594.37 %+28.64%
-462.04 %
Access this data via the Eulerpool API

Niox Group Stock analysis

What does Niox Group do? Circassia Group plc is a British biotechnology company specializing in the development of therapies for respiratory diseases. The company was founded in 2006 and is headquartered in Oxford. Circassia was founded by Steve Harris, who previously worked for the biopharmaceutical company Xenova Group plc. In its early years, the company focused on research and development of therapies for allergies and asthma. In 2014, Circassia went public on the London Stock Exchange. The company has developed an innovative business model that focuses on using its proprietary technology platform to identify novel therapy candidates. It works closely with pharmaceutical companies and other partners to accelerate the development of its therapy products and license its technology platform. Circassia's main focus is on developing therapies for respiratory diseases, particularly allergic asthma and chronic obstructive pulmonary disease (COPD). It has a range of products currently in various stages of clinical development. One of its leading products is NIOX VERO, a diagnostic device used to measure inflammation in the airways and improve the diagnosis of patients with asthma or COPD. Circassia also has a promising pipeline of therapy candidates, including Flutiform® (fluticasone propionate/formoterol fumarate), an inhaled medication for the treatment of asthma developed in collaboration with Japanese pharmaceutical company Kyorin. Additionally, the company has developed two novel drugs in the field of allergic rhinoconjunctivitis, one of which is currently being tested in phase III studies, while the other is nearing completion of phase II development. In conclusion, Circassia has established itself as an innovative biotechnology company focused on the development of therapies for respiratory diseases. It has a promising pipeline of therapy candidates at various stages of clinical development. The Circassia business model is based on utilizing its proprietary technology platform to identify and develop novel therapy candidates. Niox Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Niox Group stock

Net Profit Margin of Niox Group is 8.85 % in 2026.

Net Profit Margin of Niox Group changed from 29.08 % to 8.85 %, representing a -69.56% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Niox Group since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Niox Group with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

Margins — Niox Group

All Key Metrics — Niox Group